Tirzepatide ���子背景与靶点 — Beginner to Advanced

By Editorial Desk · published 2026-02-03 · last reviewed 2026-02-23 · Blog

Everything below concerns incretin receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-02-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tirzepatide 分子背景与靶点

在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。

脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。

Dual Incretin Receptor Pharmacology

At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.

Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.

Tirzepatide at a glance

Molecular Background and Dual Receptor Action

Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.

Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.

Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.

Related pages on this site

• Sustainable collection
• Tracked summary
• Standard briefing
• Optimized primer
• Connected reference
• Verified comparison
• Automated handbook
• Balanced summary

Tirzepatide Pharmacology and Development History

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Molecular Background and Receptor Pharmacology

Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.

The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.

Analytical Methods And Storage Stability

The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.

Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.

Identity and purity of tirzepatide are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Because the molecule carries several modifications, gradient conditions are adjusted to resolve the intact peptide from deamidation and oxidation products. Enzymatic digestion followed by peptide mapping confirms the primary sequence and locates specific modifications. Quantitation in biological matrices typically uses liquid chromatography with tandem mass spectrometry after solid-phase extraction. Immunoassays are used less often, since antibody cross-reactivity with closely related peptides can bias results.

Notes from published material

== Visual rehabilitation and cataract surgery after RK == The PERK study demonstrated that people who undergo RK continue to drift toward hyperopia ("farsightedness"). Additionally, many of these people have reached the age where presbyopia occurs. Some also develop cataracts. Their vision can still be restored with Epi-LASIK, photorefractive keratectomy, LASIK or phakic lens extraction, or cataract surgery. The corneal curvature has to remeasured and modified by history, central keratometry, or contact lens method. Selecting intraocular lenses for cataract surgery in patients who have undergone any refractive surgery has proven challenging and is associated with decreased accuracy in lens selection. RK is associated with increased inaccuracy compared to other refractive procedures such as LASIK and PRK. This is due to difficulty measuring the corneal curvature of post-RK corneas as well as difficulty identifying an effective lens position using standard lens calculations. Additional methods have been introduced to improve the accuracy of IOL calculations. Multifocal IOL insertion in eyes that have undergone RK have not been associated with good outcomes and are generally not recommended.

The 2024 edition of the FAO report The State of Food and Agriculture 2024 adopts an agrifood systems typology with six categories – protracted crisis, traditional, expanding, diversifying, formalizing and industrial – to reveal that different systems face unique challenges and require targeted interventions. The typology uses a set of four variables, comprising agricultural value added per worker, number of supermarkets per capita, diet diversity, and urbanization. It is based on the food systems typology developed by Marshall et al. (2021) with the aim to offer a distinct classification of countries based on various aspects of their national agrifood systems, serving as a valuable addition to context-specific studies. The FAO typology adds the category for protracted crises to address the major disruptions caused by prolonged conflicts and vulnerabilities in agrifood systems, following the designation made in the "Global Report on Food Crises."

=== Customer base === Officially, Sato says that its products are for business use only, for example for the use of food-processing industries or food-and-drink businesses (e.g. restaurant, café, sweets shop, bakery shop, etc.). Mainly, its products are to be used as food additives. Other than purposes for test sale, research, etc., it has never been sold for eating or drinking, including personal use or home use. In June 1982, Sato started production and sales for the drinking powdered alcohol, as test case. Its name is "powdered cocktail Alcock-Light cocktail" ("粉末カクテル 'アルコック・ライトカクテル' "). At least, during some years, it seems that had continued to test sales.

== Treatment in the future == N-terminal acetylation plays a larger role overall in cell homeostasis and changing one of the NATs has a large impact, mostly due to the vast number of substrates that are subjected to N-terminal acetylation. The mechanism and impact on the proteome level are much needed to be studied, to understand the molecular mechanisms underlying the phenotypes of the affected individuals. There could be many proteins involved in such mechanisms, and this needs to be studied to reveal new angles for improved treatment.

Sources: en.wikipedia.org

Further detail

By further optimizing the CNTs and CNT fibers, CNT fibers with improved electrical properties could be developed. CNT-based yarns are suitable for applications in energy and electrochemical water treatment when coated with an ion-exchange membrane. Also, CNT-based yarns could replace copper as a winding material. Pyrhönen et al. (2015) have built a motor using CNT winding.

Brian Clarke, Artist. For services to Art. Ronald Dennis, , Chair, Podium Analytics and Patron, Tommy's Campaign. For services to Industry and to Charity. Gregory Doran, lately Artistic Director, Royal Shakespeare Company. For services to the Arts. Athelstan Joseph Michael Eavis, , Founder and Leader, Glastonbury Festival. For services to Music and to Charity. Professor William John Edmunds, , Professor, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine. For services to Epidemiology. John Patrick Griffin, Founder, Addison Lee. For services to Business and to Charity. Stephen Alan Michael Hester, Chair, Easyjet and Chair, Nordea. For services to Business and to the Economy. David Charles Holmes, , Chief Executive Officer, Family Action. For services to Children and Families. Professor Amritpal Singh Hungin, , Emeritus Professor of General Practice, Newcastle University. For services to Medicine. Professor John Peter Iredale, , lately Interim Executive Chair, Medical Research Council. For services to Medical Research. The Right Honourable Sajid Javid, , Member of Parliament for Bromsgrove. For Political and Public Service. Timothy Randall Martin, Founder and Chair, Wetherspoons. For services to Hospitality and to Culture. Professor Alexander McCall Smith, , Author and Academic. For services to Literature, to Academia and to Charity Professor Neil James McCready Mortensen, lately President, Royal College of Surgeons of England. For services to Surgery. Gerald Maurice Ronson, , For services to Philanthropy and to the Jewish Community.

Standard peptides synthesized from amino acids labeled with stable isotope atoms serve as internal standards for serial dilutions of a sample. These allow for later absolute quantification of proteins and post-translational modifications by mass spectrometry. This technique has been adapted to absolute quantification of proteases, deciphering both activity states and total amounts in biological samples. This is thanks to trypsin treatment for mass spectrometry generating peptides specific to inactive zymogen precursors, active proteases, or common to both forms. PSPs is one form of standard peptide for absolute quantification and Standard of the Expressed Protease (STEP) is the other. The major difference between the two is PSP sequences are designed to mimic tryptic peptides that contain sequences spanning the zymogen's pro-domain and the protease's final form, whereas STEP sequences match tryptic peptide sequences found in both forms of the protease. This capitalizes on protease activation, where the zymogen's pro-domain is cleaved off and the final form lacks that domain. Experiments using iTRAQ labeling and LC-MS/MS with STEP and PSP peptide internal standards have successfully quantified total and active protease levels in biological samples. One major drawback for this approach is the inability to account for inhibitor bound enzymes. It is also difficult to ensure standard peptides can be generated for this method for each and every protease for study.

=== Vaccinating newborns === In presence of a communicable diseases, one of the main tasks is that of eradicating it via prevention measures and, if possible, via the establishment of a mass vaccination program. Consider a disease for which the newborn are vaccinated (with a vaccine giving lifelong immunity) at a rate

25 December – Gull New Zealand and NPD announce plans to merge their New Zealand operations, subject to approval from the Commerce Commission. 29 December — Gale force winds disrupt camping grounds and festivals, down trees and cause power outages in the upper North Island and Buller District in the South Island's West Coast Region. 30 December — Strong winds cause power disruptions to 10,000 homes and at least 50 cellphone towers in the Tasman District. 31 December – The 2026 New Year Honours are announced.

Sources: en.wikipedia.org

Frequently asked questions